Business Wire

Brightcove Launches Cloud Playout 2.0, Providing One Experience for Media Companies to Create, Distribute and Monetize Linear Channels

Share

Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, announces the launch of Cloud Playout 2.0, offering customers new ways to create linear channels, monetize their media, and streamline their workflows in one platform.

Brightcove’s Cloud Playout 2.0 allows users to leverage their existing content catalog and live streams to build a channel in minutes. The enhanced Cloud Playout includes a linear scheduler to create an electronic program guide (EPG), which can be displayed on apps and FAST platforms. Once a channel is built, media companies can operationalize the distribution of their linear channels to owned-and-operated (O&O) properties or FAST platforms. Managing this end-to-end experience within the Brightcove platform allows media companies to optimize their content with first-party data and analytics and control their ad monetization.

“Cloud Playout 2.0 gives media companies an efficient way to grow reach, increase engagement, and monetize their content,” said Scott Levine, Chief Product Officer at Brightcove. “This expansion creates a centralized platform for driving new business models, content windows, and experiences, allowing our customers to save time, money and resources. Cloud Playout 2.0 works with our leading monetization and insights tools to ensure every stream drives business value and enables our customers to delight their audience.”

Cloud Playout 2.0 helps media companies with:

  • Reach and Engagement: Create channels on their owned websites and apps to increase viewer engagement and extend their reach by delivering those channels to new audiences and markets with FAST aggregators.
  • Monetization: Adapt their monetization strategy across channels to increase revenue with a multi-tier approach, including Brightcove’s
  • Server-side ad Insertion (SSAI) to manage ad placement durations and bypass inconvenient ad blockers without diminishing quality and the user experience with issues like prolonged buffering.
  • Ad Monetization service to maximize ad revenue through full-stack or unsold ad inventory.
  • Free, ad-supported (FAST) channels to reach new audiences and drive viewers to subscription VOD catalogs to explore new releases and premium content.
  • Test and iterate ad rules across channels in minutes to improve revenue.
  • Efficiency: Create efficient workflows that run schedules in one platform. Customers can create and manage complex schedules for their channels while offering a VOD streaming service and live events through one platform. The linear scheduler enables users to easily search, add assets and channels, and see potential conflicts. From there, customers can convert schedules into an EPG to keep audiences up to date on the latest content.
  • Insights: Cloud Playout 2.0 works with Brightcove’s insights and analytics solutions so media companies can assess viewing habits and content performance to inform their programming and promotion strategies.

For more information, visit Brightcove.com.

About Brightcove Inc.

Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X (Formerly Twitter), Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
press@brightcove.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 14:00:00 EET | Press release

The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what and how people will be drinking in 2026. “Gen Z isn’t drinking less, they’re simply drinking earlier, lighter, and with more intent

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 14:00:00 EET | Press release

AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, Chair of AdvanCell. “Her leadership and experience positions AdvanCell to drive its next phase of growth, with the United States now a major strategic focus as the company advances 212Pb

MSCI Announces Baer Pettit to Retire as President17.11.2025 14:00:00 EET | Press release

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s strategy and success,” said MSCI Chairman and CEO Henry Fernandez. “I would like to thank Bae

Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 13:58:00 EET | Press release

Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi

Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye